@article{LeyhEhmerRoessleretal.2022,
  author    = {Leyh, Catherine and Ehmer, Ursula and Roessler, Daniel and Philipp, Alexander B. and Reiter, Florian P. and Jeliazkova, Petia and Jochheim, Leonie S. and Jeschke, Matthias and Hammig, Janina and Ludwig, Johannes M. and Theysohn, Jens M. and Geier, Andreas and Lange, Christian M.},
  title     = {Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {8},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14081975},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270765},
  year      = {2022},
  abstract  = {The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5\%), whereas 132 patients (83.5\%) had preserved liver function. In total, 72 patients (44\%) discontinued systemic therapy after first-line therapy while 51 (31\%) and 31 (19\%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.},
  language  = {en}
}